Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Nola Hylton, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentRadiology
    Address1550 4th Street, Bldg 19B
    San Francisco CA 94158
    Phone415-885-7511
    vCardDownload vCard

      Collapse Biography 
      Collapse Awards and Honors
      Academy of Radiology Research 2013Distinguished Investigator
      Susan G. Komen for the Cure's2010Scientific Advisory Council
      Komen2010Cure Scholar Award
      American College of Radiology Imaging Network2003Outstanding Contribution Award
      American Cancer Society 2003Research Scholar
      Radiology 1987 - 1988Editor's Recognition Award with Distinction
      Stanford University1979Graduate Professional Opportunities Program Fellowship
      Bell Telephone Laboratories 1975Undergraduate Fellowship

      Collapse Overview 
      Collapse Overview
      Nola Hylton, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging, Co-Director of the Breast Cancer Research Interest Group, and Director of the Breast Imaging Research Group at the University of California, San Francisco. Dr. Hylton received her BS in Chemical Engineering from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1979, and she obtained her PhD in Applied Physics from Stanford University, California in 1985.

      Dr. Hylton has been integrally involved in the development of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer. Dr. Hylton is an internationally known leader in the field of breast MRI for more than 20 years. Her search has addressed the clinical optimization and evaluation of breast MRI technology. Her current research program focuses on the development and clinical evaluation of MRI techniques for characterizing breast cancers and assessing their response to treatment. Her laboratory collaborates closely with a multi-disciplinary team of radiologists, surgeons, oncologists, and science researchers nation wide. This is to optimize MRI techniques for the clinical management of breast cancer patients.

      Dr. Hylton is among the first group of scholars named the Susan G. Komen for the Cure’s Scientific Advisory Council. She served as co-leader for the DHHS office of Women’s Health International Working Group where she identified and addressed barriers to clinical dissemination of breast MRI. She also served as the institutional Principal Investigator of the NCI International Breast MRI Consortium, which is the first large multi-center clinical trial evaluating breast MRI for breast cancer diagnosing and staging.

      Dr. Hylton has over 80 published research articles, and she has written 13 book chapters and over 130 abstracts.

      Expertise:
      Breast Imaging

      Specialty:
      Breast cancer imaging, breast MRI

      Professional Interests:
      Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging

      Education and Training:
      • Bachelor of Science: Massachusetts Institute of Technology (MIT), Cambridge - Chemical Engineering
      • Doctor of Philosophy: Stanford University, California - Applied Physics

      Collapse Interests
      Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse NIH Awarded Grants

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM, et al. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 Mar 7. PMID: 26949897.
        View in: PubMed
      2. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. PMID: 26886725; PMCID: PMC4757528.
      3. Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL. Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res. 2016 Jan 15; 22(2):284-90. PMID: 26773162.
        View in: PubMed
      4. Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, et al. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2015 Dec 1; 150013. PMID: 26624971.
        View in: PubMed
      5. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Res. 2015; 17(1):95. PMID: 26174168.
        View in: PubMed
      6. Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. PMID: 26244152.
        View in: PubMed
      7. Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF. Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res. 2015; 17(1):77. PMID: 26041651.
        View in: PubMed
      8. Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD. Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. PLoS One. 2015; 10(3):e0122151. PMID: 25816249.
        View in: PubMed
      9. Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N. Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. J Magn Reson Imaging. 2015 Oct; 42(4):908-19. PMID: 25758543.
        View in: PubMed
      10. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1; 21(13):2911-5. PMID: 25712686.
        View in: PubMed
      11. Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN. Extra-mammary findings on breast MRI: a pictorial review. Clin Imaging. 2015 Jul-Aug; 39(4):547-52. PMID: 25772531.
        View in: PubMed
      12. Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B. Lesion morphology on breast MRI affects targeted ultrasound correlation rate. Eur Radiol. 2015 May; 25(5):1279-84. PMID: 25500714.
        View in: PubMed
      13. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83. PMID: 24807204.
        View in: PubMed
      14. Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7. PMID: 24772216; PMCID: PMC3998684.
      15. Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Transl Oncol. 2014 Feb; 7(1):65-71. PMID: 24772209; PMCID: PMC3998685.
      16. Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galb N CJ, Meyer CR, Ross BD. Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol. 2014 Feb; 7(1):101-10. PMID: 24772213; PMCID: PMC3998680.
      17. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100. PMID: 24772212; PMCID: PMC3998689.
      18. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82. PMID: 24347097.
        View in: PubMed
      19. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653. PMID: 24324712; PMCID: PMC3852736.
      20. Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. J Magn Reson Imaging. 2014 Sep; 40(3):674-81. PMID: 24214467; PMCID: PMC4014534 [Available on 09/01/15].
      21. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 2013 Nov-Dec; 19(6):650-8. PMID: 24165314; PMCID: PMC4036640.
      22. McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13. PMID: 24719242; PMCID: PMC3983569 [Available on 05/01/15].
      23. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83. PMID: 23933948; PMCID: PMC3960004.
      24. Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46. PMID: 23928243.
        View in: PubMed
      25. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61. PMID: 23878283; PMCID: PMC3807081.
      26. Mukhtar RA, Yau C, Rosen M, Tandon VJ, Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. PMID: 23780381; PMCID: PMC3824937.
      27. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82. PMID: 23701101.
        View in: PubMed
      28. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9. PMID: 23701102.
        View in: PubMed
      29. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013 Aug; 13(4):280-6. PMID: 23664819.
        View in: PubMed
      30. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969. PMID: 23667451; PMCID: PMC3646993.
      31. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9. PMID: 23570936.
        View in: PubMed
      32. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83. PMID: 23436342; PMCID: PMC3939707.
      33. Hylton N. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 2013 Jan; 266(1):367. PMID: 23390630.
        View in: PubMed
      34. Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM. Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Res. 2012; 14(4):R107. PMID: 22800711; PMCID: PMC3680938.
      35. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72. PMID: 22623692; PMCID: PMC3359517.
      36. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8. PMID: 22652232.
        View in: PubMed
      37. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152; PMCID: PMC3434983.
      38. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
      39. Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. Acad Radiol. 2012 May; 19(5):526-34. PMID: 22197382; PMCID: PMC3319166.
      40. Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magn Reson Imaging. 2011 Nov; 29(9):1215-21. PMID: 21920686; PMCID: PMC3199288.
      41. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33. PMID: 21843942; PMCID: PMC4087114.
      42. McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. NMR Biomed. 2011 Jul; 24(6):712-20. PMID: 21692116.
        View in: PubMed
      43. Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD. Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model. Magn Reson Med. 2011 Dec; 66(6):1722-30. PMID: 21688315; PMCID: PMC3186821.
      44. Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N. Quantification of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging. 2011 May; 33(5):1229-34. PMID: 21509883; PMCID: PMC3081108.
      45. Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN. MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy. AJR Am J Roentgenol. 2011 Apr; 196(4):W471-5. PMID: 21427313.
        View in: PubMed
      46. Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN. Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions? Acad Radiol. 2011 Jun; 18(6):716-21. PMID: 21420333.
        View in: PubMed
      47. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr; 3(4):490-6. PMID: 21416100; PMCID: PMC3698966.
      48. Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar; 11(1):33-8. PMID: 21421520.
        View in: PubMed
      49. Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Pettee Gabriel K, Kriska A, Ruder EH, Fang CY, Barton BA. Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study. Cancer Epidemiol Biomarkers Prev. 2010 Jun; 19(6):1545-56. PMID: 20501774; PMCID: PMC2883023.
      50. Le-Petross HC, Hylton N. Role of breast MR imaging in neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2010 May; 18(2):249-58, viii-ix. PMID: 20494310.
        View in: PubMed
      51. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. PMID: 19728082; PMCID: PMC4087110.
      52. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
      53. Hylton NM. Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment? Radiology. 2009 Aug; 252(2):330-1. PMID: 19703876.
        View in: PubMed
      54. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Shepherd J, Gibbs J, Fan B, Noworolski S, Hylton N. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging. 2010 Jan; 28(1):8-15. PMID: 19631485; PMCID: PMC4087111.
      55. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. PMID: 19440188.
        View in: PubMed
      56. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9. PMID: 19388114.
        View in: PubMed
      57. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
        View in: PubMed
      58. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008 Jul; 248(1):79-87. PMID: 18566170.
        View in: PubMed
      59. Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol. 2008 Jun; 190(6):1630-6. PMID: 18492917.
        View in: PubMed
      60. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008 Feb 10; 26(5):791-7. PMID: 18258988.
        View in: PubMed
      61. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. PMID: 17968965; PMCID: PMC3024590.
      62. Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, Hylton NM. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med. 2007 Sep; 58(3):572-81. PMID: 17685424.
        View in: PubMed
      63. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007 Apr; 25(3):319-27. PMID: 17371720.
        View in: PubMed
      64. Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM. Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2007 Jan; 25(1):82-8. PMID: 17173311.
        View in: PubMed
      65. Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006 Oct; 192(4):520-4. PMID: 16978965; PMCID: PMC4087109.
      66. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006 Oct 1; 24(28):4603-10. PMID: 17008702; PMCID: PMC4087112.
      67. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006 Aug; 14(3):383-9, vii. PMID: 17098179.
        View in: PubMed
      68. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006 Jul 10; 24(20):3293-8. PMID: 16829653.
        View in: PubMed
      69. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006 Jan; 238(1):42-53. PMID: 16373758.
        View in: PubMed
      70. Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol. 2005 Oct 1; 92(1):9-15; discussion 15-6. PMID: 16180217.
        View in: PubMed
      71. Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct; 22(4):511-9. PMID: 16161072.
        View in: PubMed
      72. Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis CA. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol. 2005 Oct 1; 92(1):32-8. PMID: 16180227.
        View in: PubMed
      73. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt. 2005 Sep-Oct; 10(5):051503. PMID: 16292947.
        View in: PubMed
      74. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. PMID: 15908529.
        View in: PubMed
      75. Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol. 2005 Jun; 40(6):363-7. PMID: 15905723.
        View in: PubMed
      76. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005 May 1; 103(9):1898-905. PMID: 15800894.
        View in: PubMed
      77. Hylton N. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J Clin Oncol. 2005 Mar 10; 23(8):1678-84. PMID: 15755976.
        View in: PubMed
      78. Li KL, Zhu X, Hylton N, Jahng GH, Weiner MW, Schuff N. Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI. Magn Reson Med. 2005 Mar; 53(3):511-8. PMID: 15723393; PMCID: PMC1941668.
      79. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 8; 292(22):2735-42. PMID: 15585733.
        View in: PubMed
      80. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Lobo C, Demicco E, Watkins M, Shepherd J, Gibbs J, Hylton N. Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc. 2004; 3:1667-70. PMID: 17272023.
        View in: PubMed
      81. Hylton NM. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. AJR Am J Roentgenol. 2003 Sep; 181(3):677-8. PMID: 12933458.
        View in: PubMed
      82. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003 May; 10(4):381-8. PMID: 12734086.
        View in: PubMed
      83. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002 Nov; 179(5):1193-9. PMID: 12388497.
        View in: PubMed
      84. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer. 2002 Jun; 9(2):141-53. PMID: 12121836.
        View in: PubMed
      85. Partridge SC, McKinnon GC, Henry RG, Hylton NM. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging. 2001 Oct; 14(4):433-8. PMID: 11599068.
        View in: PubMed
      86. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. PMID: 11456056.
        View in: PubMed
      87. Kinkel K, Hylton NM. Challenges to interpretation of breast MRI. J Magn Reson Imaging. 2001 Jun; 13(6):821-9. PMID: 11382939.
        View in: PubMed
      88. Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, Barclay J, Schnall MD. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging. 2001 Jun; 13(6):889-95. PMID: 11382949.
        View in: PubMed
      89. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am. 2001 May; 9(2):321-32, vi. PMID: 11493422.
        View in: PubMed
      90. Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000 Dec; 175(6):1577-84. PMID: 11090379.
        View in: PubMed
      91. Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep. 2000 Nov; 2(6):572-81. PMID: 11122895.
        View in: PubMed
      92. Hylton NM. Suspension of breast-feeding following gadopentetate dimeglumine administration. Radiology. 2000 Aug; 216(2):325-6. PMID: 10924547.
        View in: PubMed
      93. Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol. 2000 Jul; 175(1):35-43. PMID: 10882243.
        View in: PubMed
      94. Hylton N. Dedicated Breast MRI Systems Working Group report. J Magn Reson Imaging. 1999 Dec; 10(6):1006-9. PMID: 10581519.
        View in: PubMed
      95. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am. 1999 May; 7(2):411-20, x. PMID: 10382170.
        View in: PubMed
      96. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999 Jan; 17(1):110-9. PMID: 10458224.
        View in: PubMed
      97. Partridge SC, Heumann EJ, Hylton NM. Semi-automated analysis for MRI of breast tumors. Stud Health Technol Inform. 1999; 62:259-60. PMID: 10538368.
        View in: PubMed
      98. Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J. 1999 Jan; 5(1):13-21. PMID: 11348250.
        View in: PubMed
      99. Hylton NM, Kinkel K. Technical aspects of breast magnetic resonance imaging. Top Magn Reson Imaging. 1998 Feb; 9(1):3-16. PMID: 9617899.
        View in: PubMed
      100. Bourne MW, Margerun L, Hylton N, Campion B, Lai JJ, Derugin N, Higgins CB. Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body. J Magn Reson Imaging. 1996 Mar-Apr; 6(2):3O5-1O. PMID: 9132094.
        View in: PubMed
      101. Hylton NM, Frankel SD. Imaging techniques for breast MR imaging. Magn Reson Imaging Clin N Am. 1994 Nov; 2(4):511-25. PMID: 7489305.
        View in: PubMed
      102. Hylton NM, Simovsky I, Li AJ, Hale JD. Impact of section doubling on MR angiography. Radiology. 1992 Dec; 185(3):899-902. PMID: 1438782.
        View in: PubMed
      103. Hylton NM, Du LN, Winkler M. MRA: how it's done and what it shows. Diagn Imaging (San Franc). 1990 Jun; 12(6):117, 120-5. PMID: 10149368.
        View in: PubMed
      104. Hylton NM, Chung WS, Botvinick EH, Schiller NB, Sheldon P, Kaufman L. Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries. J Digit Imaging. 1990 Feb; 3(1):34-7. PMID: 2092801.
        View in: PubMed
      105. Hylton NM. Characterization of arterial blood flow using magnetic resonance imaging techniques. Monogr Atheroscler. 1990; 15:32-42. PMID: 2296250.
        View in: PubMed
      106. Crooks LE, Arakawa M, Hylton NM, Avram H, Hoenninger JC, Watts JC, Hale JD, Kaufman L. Echo-planar pediatric imager. Radiology. 1988 Jan; 166(1 Pt 1):157-63. PMID: 3336674.
        View in: PubMed
      107. Mills TC, Ortendahl DA, Hylton NM, Crooks LE, Carlson JW, Kaufman L. Partial flip angle MR imaging. Radiology. 1987 Feb; 162(2):531-9. PMID: 3797669.
        View in: PubMed
      108. Crooks LE, Hylton NM, Ortendahl DA, Posin JP, Kaufman L. The value of relaxation times and density measurements in clinical MRI. Invest Radiol. 1987 Feb; 22(2):158-69. PMID: 3557889.
        View in: PubMed
      109. Ortendahl DA, Posin JP, Hylton NM, Mills CM. Optimal visualization of the cerebrospinal fluid on MRI. AJNR Am J Neuroradiol. 1986 May-Jun; 7(3):403-7. PMID: 3085445.
        View in: PubMed
      110. Hylton NM, Ortendahl DA. Information processing in magnetic resonance imaging. Crit Rev Diagn Imaging. 1986; 26(4):325-58. PMID: 3545683.
        View in: PubMed
      111. Posin JP, Ortendahl DA, Hylton NM, Kaufman L, Watts JC, Crooks LE, Mills CM. Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions. Radiology. 1985 Jun; 155(3):719-25. PMID: 4001375.
        View in: PubMed
      112. Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Watts JC, Kaufman L, Arakawa M, Hoenninger JC, et al. Multiple spin-echo magnetic resonance imaging. Radiology. 1985 May; 155(2):437-42. PMID: 3983396.
        View in: PubMed
      113. Ortendahl DA, Hylton N, Kaufman L, Watts JC, Crooks LE, Mills CM, Stark DD. Analytical tools for magnetic resonance imaging. Radiology. 1984 Nov; 153(2):479-88. PMID: 6091173.
        View in: PubMed
      114. Ortendahl DA, Hylton NM, Kaufman L, Crooks LE. Signal to noise in derived NMR images. Magn Reson Med. 1984 Sep; 1(3):316-38. PMID: 6571562.
        View in: PubMed
      115. Brant-Zawadzki M, Bartkowski HM, Ortendahl DA, Pitts LH, Hylton NM, Nishimura MC, Crooks LE. NMR in experimental cerebral edema: value of T1 and T2 calculations. AJNR Am J Neuroradiol. 1984 Mar-Apr; 5(2):125-9. PMID: 6422714.
        View in: PubMed
      Nola's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP